NasdaqGS - Delayed Quote • USD
Enanta Pharmaceuticals, Inc. (ENTA)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:20 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 7 | 7 | 8 | 8 |
Avg. Estimate | -1.33 | -1.23 | -5.09 | -4.67 |
Low Estimate | -1.63 | -1.65 | -6.55 | -6.69 |
High Estimate | -1.11 | -0.91 | -4.35 | -3.35 |
Year Ago EPS | -1.79 | -1.86 | -6.38 | -5.09 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 7 | 7 | 6 | 7 |
Avg. Estimate | 16.52M | 16.88M | 67.82M | 74.92M |
Low Estimate | 14M | 14M | 59M | 50M |
High Estimate | 18M | 20M | 72.6M | 111.94M |
Year Ago Sales | -- | -- | 79.2M | 67.82M |
Sales Growth (year/est) | -- | -- | -14.40% | 10.50% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -1.98 | -2.34 | -2.15 | -1.19 |
EPS Actual | -1.79 | -1.86 | -1.33 | -1.58 |
Difference | 0.19 | 0.48 | 0.82 | -0.39 |
Surprise % | 9.60% | 20.50% | 38.10% | -32.80% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -1.33 | -1.23 | -5.09 | -4.67 |
7 Days Ago | -1.33 | -1.23 | -5.09 | -4.67 |
30 Days Ago | -1.33 | -1.23 | -5.09 | -4.67 |
60 Days Ago | -1.35 | -1.22 | -5.13 | -4.82 |
90 Days Ago | -1.24 | -1.12 | -5.15 | -4.71 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | ENTA | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 25.70% | -- | -- | 6.50% |
Next Qtr. | 33.90% | -- | -- | 12.00% |
Current Year | 20.20% | -- | -- | 5.30% |
Next Year | 8.30% | -- | -- | 13.10% |
Next 5 Years (per annum) | -- | -- | -- | 11.09% |
Past 5 Years (per annum) | -10.60% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | JP Morgan: Underweight to Underweight | 2/8/2024 |
Maintains | Oppenheimer: Perform to Perform | 11/22/2023 |
Maintains | HC Wainwright & Co.: Buy to Buy | 11/21/2023 |
Maintains | JMP Securities: Outperform to Outperform | 11/21/2023 |
Maintains | HC Wainwright & Co.: Buy to Buy | 10/23/2023 |
Maintains | RBC Capital: Sector Perform to Sector Perform | 10/2/2023 |
Related Tickers
ITOS iTeos Therapeutics, Inc.
10.80
+1.89%
REPL Replimune Group, Inc.
6.42
+4.39%
STRO Sutro Biopharma, Inc.
3.4200
0.00%
BCAB BioAtla, Inc.
2.5400
+12.89%
IKNA Ikena Oncology, Inc.
1.3000
-0.76%
PTGX Protagonist Therapeutics, Inc.
25.15
+1.99%
MORF Morphic Holding, Inc.
28.07
+0.32%
XNCR Xencor, Inc.
19.98
+3.90%
KALV KalVista Pharmaceuticals, Inc.
10.78
+2.76%
CRGX CARGO Therapeutics, Inc.
18.68
+2.19%